Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?

Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.

Knee joint

Pfizer Inc. and Eli Lilly & Co. said on July 18 that both doses of their nerve growth factor (NGF) inhibitor tanezumab met all three co-primary endpoints in a Phase III osteoarthritis pain study, but what remains to be seen is if the biologic is safe enough to satisfy regulators.

This drug class has a long history with clinical holds due to safety concerns, but Pfizer and Lilly reported that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D